Who is sponsoring NCT00157339?

NCT00157339 is sponsored by Eli Lilly and Company.

What condition does NCT00157339 study?

NCT00157339 studies Diabetes Mellitus, Asthma, Pulmonary Disease, Chronic Obstructive.

What drugs are being tested in NCT00157339?

Interventions: Human Insulin Inhalation Powder, injected insulin.

What is the status of NCT00157339?

NCT00157339 is currently COMPLETED.

Last reviewed 2019-09-09 · How we verify

A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma

NCT00157339 Phase 3 COMPLETED

Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD. Patients will be treated for 12 months with a 2 month follow up period.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 3
Status	COMPLETED
Enrolment	299
Start date	2005-08
Completion	2008-05

Conditions

Diabetes Mellitus
Asthma
Pulmonary Disease, Chronic Obstructive

Interventions

Human Insulin Inhalation Powder
injected insulin

Primary outcomes

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. — 12 months

Countries

United States, Argentina, Bulgaria, Canada, Chile, Colombia, Croatia, Hong Kong, Hungary, India, Mexico, Philippines, Puerto Rico, Singapore, Taiwan, Thailand